From Analysis:
What blood-brain barrier permeability changes serve as early biomarkers for neurodegeneration, and what CSF/blood biomarker panels can detect them?
Matrix metalloproteinase-9 (MMP-9) degrades tight junction proteins (claudin-5, occludin, ZO-1) and extracellular matrix components of the neurovascular unit. The balance between MMP-9 and its inhibitor TIMP-1 determines the extent of BBB paracellular leakage. An elevated MMP-9/TIMP-1 ratio in CSF may serve as an early biomarker for neurodegeneration, but significant confounds from systemic inflammation and the invasive nature of CSF collection limit clinical utility. Historical failure of MMP-9 inhibitors in oncology and cardiovascular disease also weighs against therapeutic development.
No AI visual card yet
Curated pathway diagram from expert analysis
flowchart TD
A["Elevated MMP-9 Activity"] -->|"Degrades"| B["Tight Junction Protein Degradation"]
B -->|"Claudin-5, occludin, ZO-1"| C["BBB Paracellular Leakage"]
C -->|"Neurovascular unit disruption"| D["Neurodegeneration"]
A -->|"Reduced inhibition"| E["Decreased TIMP-1 Levels"]
A -->|"Imbalance"| F{"MMP-9/TIMP-1 Ratio Elevation"}
F -->|"Early biomarker signal"| G["CSF Biomarker Potential"]
F -->|"Correlates with severity"| D
H["Systemic Inflammation"] -->|"Confound factor"| F
H -->|"Alternative source"| A
I["Invasive CSF Collection"] -.->|"Clinical utility limitation"| G
J["Historical MMP-9 Inhibitor Failure"] -.->|"Therapeutic development barrier"| K["Therapeutic Development Challenges"]
A -.->|"Target engaged"| J
Title: Circulating Soluble PDGFRβ Reflects Pericyte Loss and Precedes Cognitive Decline in Neurodegeneration
Description: Pericyte degeneration is among the earliest events in Alzheimer's disease (AD) and vascular dementia, preceding amyloid deposition and cognitive symptoms. Damaged pericytes release the ectodomain of platelet-derived growth factor receptor β (sPDGFRβ) into the bloodstream, making it a peripheral indicator o
I will systematically evaluate each hypothesis for mechanistic plausibility, specificity, technical feasibility, and potential confounds. Where applicable, I will identify issues that span multiple hypotheses.
Based on the critical evaluation, three hypotheses warrant detailed feasibility analysis. I'll assess each for practical drug development viability.
Biomarker Utility: HIGH — sPDGFRβ functions as a pharmacodynamic/response biomarker rather than a direct therapeutic target. The underlying PDGFRβ signaling axis, however, represents a legitimate therapeutic target.
Therapeutic Approaches:
| Strategy | Agent Class | De
{"ranked_hypotheses": [{"title": "Circulating Soluble PDGFRβ Reflects Pericyte Loss and Precedes Cognitive Decline in Neurodegeneration", "description": "Soluble PDGFRβ (sPDGFRβ) is released into the bloodstream upon pericyte damage, serving as a peripheral indicator of blood-brain barrier (BBB) pericyte coverage loss. Elevated plasma sPDGFRβ correlates with BBB leakage and cognitive decline trajectories. The mechanism involves ADAM10/ADAM17-mediated ectodomain shedding of PDGFRβ from damaged pericytes. This hypothesis has the strongest evidence base with human validation in Alzheimer's dise
No clinical trials data available
Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.
No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.
Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.
High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.
Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.
Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
No DepMap CRISPR Chronos data found for MMP9, TIMP1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No governance decisions recorded for this hypothesis.
Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.
No related hypotheses found
Molecular pathway showing key causal relationships underlying this hypothesis
graph TD
CLDN5["CLDN5"] -->|maintains| paracellular_BBB_integrit["paracellular_BBB_integrity"]
AQP4["AQP4"] -->|regulates| glymphatic_function["glymphatic_function"]
MMP9["MMP9"] -->|cleaves tight junc| CLDN5_1["CLDN5"]
AQP4_2["AQP4"] -->|released in| astrocyte_exosome["astrocyte_exosome"]
NEFL["NEFL"] -->|transport via tran| CAV1["CAV1"]
beta_catenin_signaling["beta_catenin_signaling"] -.->|suppresses| CAV1_3["CAV1"]
CLDN5_4["CLDN5"] -->|cleaved by| gamma_secretase["gamma_secretase"]
PDGFR_["PDGFRβ"] -->|ectodomain sheddin| sPDGFR_["sPDGFRβ"]
sPDGFR__5["sPDGFRβ"] -->|biomarker of| pericyte_degeneration["pericyte_degeneration"]
MMP9_TIMP1["MMP9/TIMP1"] -->|causative ratio| tight_junction_degradatio["tight_junction_degradation"]
FGA_FGB_FGG["FGA/FGB/FGG"] -->|leaks across| BBB_leakage["BBB_leakage"]
FXIII["FXIII"] -->|cross links| fibrinogen["fibrinogen"]
style CLDN5 fill:#4fc3f7,stroke:#333,color:#000
style paracellular_BBB_integrit fill:#4fc3f7,stroke:#333,color:#000
style AQP4 fill:#4fc3f7,stroke:#333,color:#000
style glymphatic_function fill:#4fc3f7,stroke:#333,color:#000
style MMP9 fill:#ce93d8,stroke:#333,color:#000
style CLDN5_1 fill:#4fc3f7,stroke:#333,color:#000
style AQP4_2 fill:#4fc3f7,stroke:#333,color:#000
style astrocyte_exosome fill:#4fc3f7,stroke:#333,color:#000
style NEFL fill:#4fc3f7,stroke:#333,color:#000
style CAV1 fill:#4fc3f7,stroke:#333,color:#000
style beta_catenin_signaling fill:#4fc3f7,stroke:#333,color:#000
style CAV1_3 fill:#4fc3f7,stroke:#333,color:#000
style CLDN5_4 fill:#4fc3f7,stroke:#333,color:#000
style gamma_secretase fill:#4fc3f7,stroke:#333,color:#000
style PDGFR_ fill:#ce93d8,stroke:#333,color:#000
style sPDGFR_ fill:#4fc3f7,stroke:#333,color:#000
style sPDGFR__5 fill:#4fc3f7,stroke:#333,color:#000
style pericyte_degeneration fill:#4fc3f7,stroke:#333,color:#000
style MMP9_TIMP1 fill:#4fc3f7,stroke:#333,color:#000
style tight_junction_degradatio fill:#4fc3f7,stroke:#333,color:#000
style FGA_FGB_FGG fill:#4fc3f7,stroke:#333,color:#000
style BBB_leakage fill:#4fc3f7,stroke:#333,color:#000
style FXIII fill:#4fc3f7,stroke:#333,color:#000
style fibrinogen fill:#4fc3f7,stroke:#333,color:#000
neurodegeneration | 2026-04-26 | completed
No comments yet. Be the first to comment!